Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label randomized comparison of semaglutide injection versus Wegovy in adults with obesity
CTR20251575Phase 3Active
- Sponsor
- Quality Peptide
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in obesity, sponsored by Quality Peptide. Started Jul 2025; status: active.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on CTR20251575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251575.